De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.

MLA

Thomas, Pepijn W. A., et al. “De-Escalation of Biological Therapy in Inflammatory Bowel Disease Patients Following Prior Dose Escalation.” European Journal of Gastroenterology & Hepatology, vol. 34, no. 5, May 2022, pp. 488–95. EBSCOhost, https://doi.org/10.1097/MEG.0000000000002336.

APA

Thomas, P. W. A., Smits, L. J. T., Te Groen, M., West, R. L., Russel, M. G. V. M., Jansen, J. M., Römkens, T. E. H., & Hoentjen, F. (2022). De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation. European Journal of Gastroenterology & Hepatology, 34(5), 488–495. https://doi.org/10.1097/MEG.0000000000002336

Chicago

Thomas, Pepijn W A, Lisa J T Smits, Maarten Te Groen, Rachel L West, Maurice G V M Russel, Jeroen M Jansen, Tessa E H Römkens, and Frank Hoentjen. 2022. “De-Escalation of Biological Therapy in Inflammatory Bowel Disease Patients Following Prior Dose Escalation.” European Journal of Gastroenterology & Hepatology 34 (5): 488–95. doi:10.1097/MEG.0000000000002336.